Full-Time

Senior Territory Manager

Posted on 8/20/2026

Inogen

Inogen

501-1,000 employees

Portable oxygen concentrators for home care

Compensation Overview

$71k - $85.2k/yr

+ Sales commission

Orlando, FL, USA

Hybrid

Hybrid role with approximately 90% territory-based, outside field sales work.

Associate's

Category
Sales & Account Management (1)
Required Skills
Microsoft Office
CRM

Get referred to Inogen

See people who can refer or advise you

Requirements
  • Associate degree in Sales, Technical, Business, Clinical, or a related field is required for the Senior Territory Manager level.
  • Three or more years of medical referral sales experience are required for the Senior Territory Manager level.
  • Intermediate proficiency with Microsoft Office is required.
  • The ability to conduct total office sales calls, product demonstrations, in-services, and presentations of clinical studies to physicians is required.
  • Strong analytical, problem-solving, and multitasking abilities are required.
  • Excellent oral and written communication skills are required.
  • Excellent planning and organizational skills are required.
Responsibilities
  • Promote the Inogen product line by increasing sales volume among new and existing customers.
  • Serve in a 90% territory-based, outside field sales role calling on physicians, healthcare teams, and facilities.
  • Meet or exceed monthly sales call targets and quotas.
  • Maintain detailed records of sales activities and customer interactions.
  • Provide and execute territory sales plans using strategic and tactical approaches that result in successful outcomes.
  • Assist with collecting required medical records for insurance submissions.
  • Comply with company policies and procedures.
  • Collaborate across teams and stakeholders to support performance and growth initiatives.
  • Act as a liaison to other departments as needed.
  • Create and execute advanced territory sales plans with strategic and tactical approaches.
  • Serve as a liaison to other departments representing the Prescriber Channel.
  • Ensure team members adhere to standard operating procedures and retrain them as necessary.
  • Make independent decisions to guide and instruct other Territory Managers.
Desired Qualifications
  • Respiratory-related referral experience with a proven track record of success is preferred.
  • Experience working with the 65+ demographic is a plus.
  • A clinical background or licensure, such as respiratory therapist or registered nurse, is preferred.
  • An associate degree in Sales, Technical, Business, Clinical, or a related field is preferred for the Level I Territory Manager qualification.

Inogen makes and sells portable oxygen concentrators for people with chronic breathing problems like COPD. These devices pull in air from the surroundings, remove nitrogen, and deliver concentrated oxygen to the user, allowing them to move around and stay independent while receiving oxygen therapy. The product is designed to be light and easy to carry, with models available to buy or rent directly from Inogen, and through a network of distributors and home medical equipment providers. What sets Inogen apart is its direct-to-consumer approach (and rental option) that bypasses traditional durable medical equipment sellers, aiming to build direct relationships with patients. The company operates in the home medical equipment market, targeting those who need long-term oxygen therapy. Its goal is to improve patients’ quality of life by providing portable, user-friendly oxygen solutions and expanding access to oxygen therapy.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Goleta, California

Founded

2001

Get referred to Inogen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • International revenue rose 14.8% in Q2 2026, the tenth straight double-digit quarter.
  • Inogen raised 2026 adjusted EBITDA guidance to about $4 million on August 6, 2026.
  • Cash reached $106.8 million with no debt, while buybacks returned $7.5 million in 2026.

What critics are saying

  • U.S. sales fell 2.3% in Q2 2026, and rental revenue dropped 11.8%.
  • Management cut 2026 revenue guidance to $355 million-$361 million on August 6, 2026.
  • Simeox needs U.S. reimbursement approval; delay traps a $500 million addressable market.

What makes Inogen unique

  • Rove, Voxy, Aurora, and Simeox turn Inogen into a multi-product respiratory platform.
  • Inogen sells directly to patients, capturing demand without durable medical equipment middlemen.
  • Yuwell invested $27.2 million in 2026, giving Inogen a global oxygen-concentrator partner.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 10th, 2026
Inogen Q2 earnings beat estimates as sales rise 3% Y/Y to $95.1M, but 2026 outlook cut

Inogen reported breakeven earnings for Q2 2026, beating the Zacks Consensus Estimate by 17.7%. This compares to an adjusted loss of 2 cents per share in the prior-year quarter. Revenues reached $95.1 million, up 3% year over year and slightly ahead of estimates. The growth was driven by strong international demand for portable oxygen concentrators, favourable exchange rates and new product contributions. International sales climbed 14.8% to $41.3 million, marking the 10th consecutive quarter of double-digit growth. However, US sales declined 2.3% to $42.3 million, whilst US rental revenues fell 11.8% to $11.6 million. Adjusted gross margin improved 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Year to date, Inogen's shares have fallen 10%.

Yahoo Finance
Aug 7th, 2026
Inogen raises 2026 EBITDA guidance to $4M on 15% international growth despite US sales headwinds

Inogen reported strong international revenue growth of 15% year-over-year in Q2 2026, marking its 10th consecutive quarter of double-digit international growth. The company's core portable oxygen concentrator unit volume grew over 12%, outpacing overall market growth. Gross margin expanded by 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Inogen raised its full-year adjusted EBITDA guidance to approximately $4 million, representing 48% growth over 2025. However, the company lowered its full-year revenue guidance to $355–361 million from $366–373 million. US sales declined 2% year-over-year due to channel mix challenges, whilst US rental revenue decreased 12%. New products Voxy and Aurora are gaining traction, with Voxy shipping over 5,000 units. Inogen maintains a strong balance sheet with $106.8 million in cash and no debt.

Startup Rise Asia
Jul 23rd, 2026
Yuwell Medical invests $27M in US respiratory firm Inogen, targets top three global ranking

Yuwell Medical has announced a strategic investment in Inogen, a US-based respiratory health company. Through its Hong Kong subsidiary, Yuwell will invest approximately $27.2 million for a 9.9% stake in Inogen's common stock. The partnership will focus on four key areas: international distribution, trademark licensing, joint research and development, and supply chain optimisation. Both companies specialise in oxygen concentrators and aim to combine their expertise across different markets. At Yuwell's 2025 Global Core Partner Conference, Chairman Alex Wu outlined the company's five-year vision to become one of the top three global players in home medical health. Yuwell identified respiratory treatment solutions, diabetes care, and emergency services as its three strategic priorities for international expansion.

Associated Press
Jul 1st, 2026
Inogen appoints Andy Reding as chief operating officer to drive growth and profitability

Inogen, a medical technology company specialising in respiratory products, has appointed Andy Reding as Chief Operating Officer, effective 6 July 2026. Reding will oversee revenue and operational performance whilst aligning cross-functional priorities as the company pursues new product launches and geographic expansion. Reding brings over 30 years of experience in medical technology. Most recently, he served as Chief Commercial Officer at Viant Medical for six years, where he led teams across 25 facilities. He previously held leadership roles at Hillrom Respiratory Health, managing sales, marketing and product development. As part of his employment, Reding will receive 130,000 restricted stock units vesting over three years. He holds an MBA from the University of South Carolina and a bachelor's degree from Marquette University.

Associated Press
May 7th, 2026
Inogen reports Q1 2026 revenue growth of 3.4%, authorises $30M share buyback program

Inogen, a medical technology company offering respiratory products, reported first-quarter 2026 revenue of $85.1 million, up 3.4% year-over-year, exceeding guidance. The company reiterated its full-year 2026 revenue outlook of $366 million to $373 million. The Beverly, Massachusetts-based firm posted a GAAP net loss of $8.3 million, compared to a $6.2 million loss in the prior-year period. Adjusted EBITDA was negative $1.4 million, down from positive $0.04 million a year earlier, due to increased research and development investments. Inogen authorised a $30 million share repurchase programme and appointed Jason Richardson as chief financial officer. The company also launched Aurora CPAP masks in the US, entering the obstructive sleep apnea market, and introduced its Rove 6 portable oxygen concentrator in Brazil.